Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Forum: Aktien User: Coronaprofiteur

The 450-patient trial began on Aug. 12 and will evaluate two unspecified low doses of the pill against a placebo, according to a study description posted Tuesday in a U.S. government database. The trial is enrolling patients with a BMI of at least 27, which falls within the World Health Organization’s overweight category. Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity. Novo’s pill has been prescribed more than 5M times since its U.S. launch in January, quickly gaining share in the competitive obesity-drug market. In the U.S., the two lower-dose versions of the pill are also priced at about half the cost of the two higher doses for self-paying customers.

Nun erfreut sich der CEO nach seinen letzten Aussagen nicht gerade grosser Popularität hier in DK....

Hättest sie schon 2 Jahre im Depot, wäre es anstrengender ...

Die Aktie ist einfach anstrengend, 1 Jahr im Depot und nix passiert.

Siehst du den Kurs in deiner 🔮❓️oder hast du eine Begründung 🤔🙈 Warum soll die Aktie über 20% steigen ❓️❓️❓️

Traurig mittlerweile, dass die Dänen immer verkaufen und uns dann die Amis hochkaufen

A fresh regulatory decision in France underpins the long-term demand outlook for Novo Nordisk's GLP-1 weight-loss medicines. As reported on August 18, 2026, France's health authorities have agreed to provide reimbursement coverage for weight-loss therapies including Wegovy, limiting use to people with severe obesity and defined comorbidities. France's health minister indicated that the cost of providing this coverage would be around EUR100 million per year, with a standard reimbursement rate of 65% but actual coverage rising to 100% for many patients due to their comorbid conditions. The target treatment population is described as around one million people, highlighting a sizable eligible pool for reimbursed GLP-1 therapy. This move positions France as the first EU country to provide permanent reimbursement under general law for these obesity drugs, creating a structural demand tailwind for Novo Nordisk's Wegovy in a major European market. For investors, the French reimbursement framework matters because it replaces a largely out-of-pocket market - where patients paid roughly EUR300 a month for injections - with an insurance-backed model that can support more sustained adherence and broader access. By tying eligibility to severe obesity and comorbidities such as cardiovascular disease, the policy also implicitly aligns reimbursement with the clinical data showing semaglutide's ability to reduce risks of heart attacks and strokes, which has already driven broader use in other health systems. https://www.ad-hoc-news.de/boerse/news/corporate-news/novo-nordisk-stock-benefits-as-france-moves-to-reimburse-wegovy-and-new/69966701

Legen sich einfach nicht fest. Vermutlich steht gerade der EU Rollout ganz oben bei den todos...

Mal wieder outperformed worden von Lilly heute. Ganz stark

Sie haben ja die Zulassung in México erhalten, aber wie ich verstanden habe werden sie bisschen später mit den Verkauf starten ? In den nächsten Quartalen war die Aussage wird es in viele mexikanischen Apotheken verfügbar sein

Ja ich glaube an die Aktie und halte sie auch aber denke ich verkaufe bei 52€. So 80 bis 90 Euro sehe ich aktuell nicht kann mich aber auch täuschen

Alle die an die Aktie glauben werden auch die 50€+ sehen.👍

Auf jeden Fall.

Hab die B

Wir dürfen gespannt sein was im September alles so veröffentlicht wird

Novo Nordisk has moved a previously undisclosed obesity drug, NNC0721-8060, into Phase 1. The 142-person trial will measure weight loss and compare it with both placebo and semaglutide. Novo has not yet disclosed the drug’s target or mechanism. $NVO